Study identifier:D5180C00034
ClinicalTrials.gov identifier:NCT05729711
EudraCT identifier:N/A
CTIS identifier:N/A
TEZSPIRE Subcutaneous Injection 210mg Specific use-results study (Long term) in patients with Bronchial asthma.
Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)
N/A
No
-
All
416
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2025 by AstraZeneca
AstraZeneca
-
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. (1) Development of related AEs (2) Contributing factors possibly having an impact on the safety and effectiveness (3) Development of unexpected related AEs
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. (1) Development of related AEs (2) Contributing factors possibly having an impact on the safety and effectiveness (3) Development of unexpected related AEs This investigation will be conducted to support the application for re-examination specified in Article 14-4 of the Act on Securing Quality, Effectiveness and Safety of Products Including Pharmaceuticals and Medical Devices.
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.